Genethon Archives

granulomatous disease orchard therapeutics

News and Trends 18 Dec 2017

British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease

Orchard Therapeutics has licensed a gene therapy for the rare genetic disorder X-linked chronic granulomatous disease (X-CGD) from the non-profit Généthon. London-based Orchard Therapeutics is adding a new program to its pipeline of gene therapies. The company has obtained an exclusive license to a lentiviral vector to treat X-linked chronic granulomatous disease and the clinical trial data […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Jun 2017

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy

Noble Généthon has teamed up with ignominious Sarepta to develop a gene therapy for the Duchenne variety of the muscle wasting disease. Dedicated to rare diseases since 1990 and more recently to gene therapy, Généthon is one of very few not-for-profit companies in European biotech. Though it has not yet brought a drug to market, it is […]

June 22, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 28 Mar 2017

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first gene therapy, Glybera, received marketing authorization from the EMA. The treatment was designed and developed by uniQure as one-off treatment for Lipoprotein Lipase Deficiency (LPLD), a […]

March 28, 2017 - 5 minutesmins - By Evelyn Warner

In Depth 21 Mar 2017

Rethinking Profits: Can a Socially Conscious Model work in Biotech?

As biopharma continues to weather a maelstrom of public scrutiny for its prices and profits, I asked executives about alternative models. Conventional wisdom in biotech is that the non-profit model can’t work in the industry: it takes a decade and billions in cash to develop a drug, with no guaranteed success. No investor would sink […]

March 21, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 14 May 2015

Selecta continues its tour around France with another collaboration

Selecta Biosciences and Généthon are collaborating to enable repeat dosing for gene therapies. The companies are combining Généthon’s expertise in the development of gene therapy vectors and Selecta’s Synthetic Vaccine Particle platform to prevent undesired immune responses. Selecta seems quite fond of collaborating with French companies. After allying with Sanofi, the US-based company has announced […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Mar 2015

Live from Bio-Europe 2015: The product development challenges in the gene therapy field

Gene Therapy is really the hot topic right now in the field of Biotech especially with technologies such as CRISPR and CAR-T therapies. The value of such companies are skyrocketing and many see the field as the next potential blockbuster therapies. Gene therapy has clearly a huge potential but also lot of challenges, let’s go through […]

March 10, 2015 - 3 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Genethon

British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Rethinking Profits: Can a Socially Conscious Model work in Biotech?

Selecta continues its tour around France with another collaboration

Live from Bio-Europe 2015: The product development challenges in the gene therapy field

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!